BMO cuts FactSet Research stock price target on valuation By Investing.com

FactSet reported Q2 FY2026 EPS $4.46 versus $4.37 expected and revenue $611M versus $604.62M, modest beats. Annual subscription value grew 6.7% and management said AI adoption is deepening client engagement, though longer-term AI risk remains unresolved. BMO cut its price target to $257 (Market Perform), Stifel cut to $248 (Hold) and Morgan Stanley to $228 (Equalweight), reflecting growth and margin concerns despite the results. Shares have surged nearly 12% over the past week and InvestingPro flags the name as still undervalued, indicating mixed investor sentiment.

Analysis

The market is rewarding the message that AI is currently increasing client engagement rather than immediately cannibalizing subscription economics; that dynamic creates a short-to-medium-term catalyst where ARPU expansion and share-of-wallet gains are realizable within 6–18 months even if longer-term commoditization pressure exists. However, the management claim that only ~10% of annual subscription value is non‑proprietary is the fulcrum: if investor skepticism is correct and the true exposure is materially higher, downside to renewal rates and pricing power could show up gradually over 12–36 months rather than as a single binary event.

Lowered share count and margin compression from near-term investments create a classic “eps smoothing” story — EPS can be propped by buybacks while underlying operating margins lag until investments mature. That implies asymmetric outcomes: upside from successful product rollouts or cross-sell (30–40%+ re-rating over 12 months if execution is strong) and non-trivial downside if investments fail to produce meaningful ARR lift (20–35% downside if churn or pricing weakness emerge).

Second-order competitive effects matter: incumbents with deeper, sticky workflows (high integration into client desktops and compliance processes) are likely to extract more lifetime value, pressuring smaller, more commoditized data vendors. Conversely, large enterprise vendors or private-equity-backed consolidators could accelerate price competition or bundle offerings, compressing growth trajectories over a 2–4 year horizon. Watch cadence of ASV disclosure, management commentary on ‘non-proprietary’ definitions, and margin trajectory — any slippage or increased disclosure that raises the non-proprietary share should produce a stage-wise re-rating within weeks to quarters.

Key Decisions for Investors

• Long equity (FDS): Initiate on a pullback of 8–12% from last week’s highs or on an intra-quarter ASV beat; position size 2–3% of portfolio. Target 30–40% upside over 12 months if ARR inflection continues; hard stop at 12–15% to cut losses if guidance/ASV tone deteriorates.
• Options hedge / leveraged bullish: Buy a 9–12 month call spread (debit) to cap cost — buy near-ITM call and sell a 25–35% OTM call to create ~1:3 risk/reward. Use this if you want exposure without funding buybacks’ off-cycle noise; capital at risk = option premium.
• Earnings/Guidance hedge: If holding shares through the next quarterly release, buy a short-dated (6–10 week) put or collar to limit downside from a surprise guidance cut; expect hedging cost in the low-single-digit percent of notional for 6–10 week protection.
• Event-driven tactical: Enter a modest pre-event long (1% position) ahead of any management day where the firm is expected to clarify the ‘non‑proprietary’ ASV methodology. If disclosure narrows ambiguity favorably, scale to target size; if disclosure increases ambiguity, exit immediately.
• Watch-list for downside pair: If disclosure shows higher non-proprietary exposure, rotate to cash or hedge by reducing beta exposure and favor defensive software names with >80% proprietary workflow lock-in; set an alert for a >15% downward revision in FY ARR growth as a trigger to short or materially hedge FDS.